Jill Feldman: Presenting COCOON and MARIPOSA together tells a much bigger story
Jill Feldman, Co-Founder of EGFR Resisters and Lung Cancer Patient and Advocate, shared a post by Eric K. Singhi, Assistant Professor at MD Anderson Cancer Center, on X:
“I have many thoughts (surprise), but ultimately, there isn’t a one-size-fits-all treatment. It’s unsettling that opinions are being formed already based on side effects without seeing the COCOON data that will be presented today.
I am a passionate and vocal advocate for QOL, but we can’t ignore the survival data. This isn’t about gaining a few extra months’ – 12 plus months is significant and should not be overlooked!
I can’t help but think personally about
- My dad would have lived to see me graduate 8th grade (he died a few weeks before), maybe even high school.
- My mom would have lived to see the birth of my daughter (she died 6 months before) and likely all of my children.
That matters, too!
While I can’t say what my parents would have chosen, I it is ultimately the patient’s/family’s choice! Every family deserves the information and opportunity to discuss all options (Informed decision-making). This respect for patient choice should be a priority.
I also feel strongly that the COCOON data should have been presented alongside the MARIPOSA data. It’s just as crucial (even more) because it addresses the significant barrier of side effects that impact whether a patient can stay on treatment. Kudos to J&J for listening to what’s important to patients and developing a study to address the side effects up front!
If QOL truly matters, then so should the data that addresses it! Presenting them together tells a much bigger story and would have changed the conversation. I implore researchers, clinicians, and conference organizers to think about this going forward.”
Quotting Eric K. Singhi‘s post:
“MARIPOSA OS data is here – what now while we await FLAURA2 OS data?
- Ami plus Laz should be part of clinic discussions.
- Managing toxicity is key. Supportive efforts are a must.
- Shared decision-making matters.
Jill Feldman, eager for your thoughts!”
More posts featuring Jill Feldman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023